Castle Biosciences (CSTL) Common Equity (2018 - 2026)

Castle Biosciences has reported Common Equity for 9 years, with the latest figure at $470.0 million in Q2 2026.

• Quarterly Common Equity rose 3.22% year-over-year to $470.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $470.0 million (up 3.22% YoY) and the FY2025 annual result came in at $470.9 million, up 3.3% from the prior year.
• Common Equity advanced to $470.0 million in Q2 2026 per CSTL's latest filing, from $461.4 million in the prior quarter.
• Over five years, Common Equity peaked at $470.9 million in Q4 2025 and troughed at $378.8 million in Q2 2023.
• A 5-year average of $425.5 million and a median of $422.8 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity slipped 10.17% in 2023, then increased 16.5% in 2024.
• Over 5 years, Common Equity stood at $399.2 million in 2022, then declined by 1.97% to $391.3 million in 2023, then increased by 16.5% to $455.8 million in 2024, then grew by 3.3% to $470.9 million in 2025, then dropped by 0.18% to $470.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $470.0 million, $461.4 million, and $470.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.